SCYL1 Antibody / N-terminal kinase-like protein

Overview

SCYL1 Antibody / N-terminal kinase-like protein is an antibody targeting SCYL1, raised in Rabbit for protein detection and localization studies where these specifications are required.

Key elements and design rationale

• Target: SCYL1.
• Antibody identity: Polyclonal (rabbit origin); Rabbit IgG.
• Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
• Format: Antigen affinity purified.
• Species reactivity: Human.
• Listed applications: WB, FACS, Direct ELISA (refer to on-page specifications for application-specific guidance).

The stated region information can help interpret whether specific isoforms or processing products are expected to be recognized.

Biological background

SCY1-like 1 (S. cerevisiae), also known as SCYL1, is a human gene which is highly conserved throughout evolution. This gene encodes a transcriptional regulator belonging to the SCY1-like family of kinase-like proteins. The protein has a divergent N-terminal kinase domain that is thought to be catalytically inactive, and can bind specific DNA sequences through its C-terminal domain. It activates transcription of the telomerase reverse transcriptase and DNA polymerase beta genes. The protein has been localized to the nucleus, and also to the cytoplasm and centrosomes during mitosis. Multiple transcript variants encoding different isoforms have been found for this gene.

Research relevance and current trends

• Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
• Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
• Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.

Common research applications

• Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
• Flow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
• ELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.

Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.

Notes for experimental interpretation

• Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
• Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
• Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
• Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.